Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent

Pouchitis is a common complication that develops after an ileal pouch-anal anastomosis after colectomy for ulcerative colitis. In some cases, pouchitis becomes chronic and refractory to conventional therapies including antibiotics, corticosteroids, immunomodulators, probiotics, and anti-inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeates, Jessica, Rashid, Mohsin
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025371/
https://www.ncbi.nlm.nih.gov/pubmed/21274444
http://dx.doi.org/10.1155/2010/860394
_version_ 1782196903653408768
author Yeates, Jessica
Rashid, Mohsin
author_facet Yeates, Jessica
Rashid, Mohsin
author_sort Yeates, Jessica
collection PubMed
description Pouchitis is a common complication that develops after an ileal pouch-anal anastomosis after colectomy for ulcerative colitis. In some cases, pouchitis becomes chronic and refractory to conventional therapies including antibiotics, corticosteroids, immunomodulators, probiotics, and anti-inflammatory drugs. We report a case of an adolescent with chronic pouchitis who not only improved with infliximab therapy but remains in long-term remission with maintenance therapy without any adverse effects. Infliximab is a safe and effective therapy for refractory pouchitis and may obviate the need for pouch removal and a permanent ileostomy.
format Text
id pubmed-3025371
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30253712011-01-27 Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent Yeates, Jessica Rashid, Mohsin Gastroenterol Res Pract Case Report Pouchitis is a common complication that develops after an ileal pouch-anal anastomosis after colectomy for ulcerative colitis. In some cases, pouchitis becomes chronic and refractory to conventional therapies including antibiotics, corticosteroids, immunomodulators, probiotics, and anti-inflammatory drugs. We report a case of an adolescent with chronic pouchitis who not only improved with infliximab therapy but remains in long-term remission with maintenance therapy without any adverse effects. Infliximab is a safe and effective therapy for refractory pouchitis and may obviate the need for pouch removal and a permanent ileostomy. Hindawi Publishing Corporation 2010 2011-01-12 /pmc/articles/PMC3025371/ /pubmed/21274444 http://dx.doi.org/10.1155/2010/860394 Text en Copyright © 2010 J. Yeates and M. Rashid. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Yeates, Jessica
Rashid, Mohsin
Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
title Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
title_full Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
title_fullStr Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
title_full_unstemmed Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
title_short Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
title_sort successful long-term use of infliximab in refractory pouchitis in an adolescent
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025371/
https://www.ncbi.nlm.nih.gov/pubmed/21274444
http://dx.doi.org/10.1155/2010/860394
work_keys_str_mv AT yeatesjessica successfullongtermuseofinfliximabinrefractorypouchitisinanadolescent
AT rashidmohsin successfullongtermuseofinfliximabinrefractorypouchitisinanadolescent

Ejemplares similares